Guiding Obstetric Care and Treatment Decisions for Women With Prior GLP-1 Receptor Agonist UseGuiding Obstetric Care and Treatment Decisions for Women With Prior GLP-1 Receptor Agonist Use
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as liraglutide and semaglutide, have revolutionized treatment of obesity. Obesity and obesity-related comorbidities increase the risks of adverse outcomes such as miscarriage, congenital malformations, preterm birth, gestational diabetes, and preeclampsia, which can have significant long-term consequences for mother and infant. By enabling women to begin pregnancy at a lower Read More
Adjuvant Chemotherapy for HR-Positive ERBB2- Negative Breast CancerAdjuvant Chemotherapy for HR-Positive ERBB2- Negative Breast Cancer
Oncology
Adjuvant Chemotherapy for HR-Positive, ERBB2 -Negative Breast CancerAdjuvant Chemotherapy for HR-Positive, ERBB2 -Negative Breast Cancer
This cohort study examines changes from 2010 to 2022 in use of adjuvant chemotherapy for early-stage hormone receptor–positive, ERBB2-negative breast cancer by age, genomic risk, and nodal involvement.
FDA approves Wegovy weight loss pill from Novo NordiskFDA approves Wegovy weight loss pill from Novo Nordisk
The Food and Drug Administration on Monday approved a pill version of Wegovy, Novo Nordisk’s blockbuster weight loss drug. The Food and Drug Administration on Monday approved a pill version of Wegovy, Novo Nordisk’s blockbuster weight loss drug.
FDA approves pill version of Novo Nordisk’s Wegovy, possibly widening accessFDA approves pill version of Novo Nordisk’s Wegovy, possibly widening access
The Food and Drug Administration on Monday approved the oral version of Novo Nordisk’s injectable weight loss drug Wegovy, making it the first GLP-1 pill to be cleared by regulators for obesity and possibly allowing many more Americans to access a highly effective treatment. The Wegovy pill, whose approval for weight loss was widely anticipated, Read More
GLP-1s don’t always work for weight loss. Researchers are trying to figure out whyGLP-1s don’t always work for weight loss. Researchers are trying to figure out why
GLP-1 weight loss drugs have transformed obesity treatment, but not everyone loses lots of weight. Researchers say figuring out why is the key to the future of this treatment method. GLP-1 weight loss drugs have transformed obesity treatment, but not everyone loses lots of weight. Researchers say figuring out why is the key to Read More
Adding Tucatinib in First-Line Maintenance Boosts PFS in HER2-Positive Breast CancerAdding Tucatinib in First-Line Maintenance Boosts PFS in HER2-Positive Breast Cancer
(MedPage Today) — At the San Antonio Breast Cancer Symposium, investigators presented results from HER2CLIMB-05, a registrational trial evaluating the addition of tucatinib (Tukysa) to trastuzumab (Herceptin) and pertuzumab (Perjeta) maintenance…
Next-Gen Oral SERD Cuts Recurrence Risk in Early Breast CancerNext-Gen Oral SERD Cuts Recurrence Risk in Early Breast Cancer
(MedPage Today) — At the San Antonio Breast Cancer Symposium, investigators reported phase III results showing that the oral selective estrogen-receptor degrader (SERD) giredestrant significantly reduced recurrence risk compared with standard…
High-fat diets make liver cells more susceptible to cancer-causing mutations, study showsHigh-fat diets make liver cells more susceptible to cancer-causing mutations, study shows
One of the biggest risk factors for developing liver cancer is a high-fat diet. A new study from MIT reveals how a fatty diet rewires liver cells and makes them more prone to becoming cancerous.
The throughline between Ozempic and ProzacThe throughline between Ozempic and Prozac
Good morning! I hope everyone has a week of many cookies and few emails ahead. You’ll hear from me once more this year, tomorrow. How safe is food in the U.S.? In any given year in the U.S., contaminated food causes around 48 million illnesses and 3,000 deaths. And food experts predict that the Trump Read More